FDA Allows Zyn Nicotine Pouches Modified Risk Label

The Food and Drug Administration authorized Philip Morris International to market its Zyn nicotine pouches with a modified risk statement indicating the products are less harmful than cigarettes, according to an announcement on June 30, 2026. The decision followed an extensive scientific review and allows the pouches to feature the statement, "Using Zyn instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis."

Key takeaways
FDA authorized Philip Morris subsidiary Swedish Match to market Zyn nicotine pouches with a modified risk claim on June 30, 2026.
The approved statement says using Zyn instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.
The authorization lasts for five years and requires ongoing studies and surveillance, including monitoring youth uptake and consumer understanding.
FDA initially cleared Zyn pouches in 2025, finding that benefits to adult cigarette smokers outweighed risks to adults and youth.

Table of Contents
What Happened
Scientific Review and Authorization Process
Requirements and Monitoring
Industry and Advocacy Response
What to Watch Next

What Happened

The FDA announced on June 30, 2026 that Philip Morris International subsidiary Swedish Match can market Zyn nicotine pouches with a modified risk statement. The authorized claim states that using Zyn instead of cigarettes puts users at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.

Bret Koplow, acting director of the FDA's Center for Tobacco Products, stated that the review of modified risk products is intended to ensure that adult users have clear, science-based information about the relative harms of tobacco products so they can make informed choices. He said the decision allows these products to be marketed with a modified risk claim that informs adults who smoke about the lower risks associated with these products.

The authorization followed the FDA's initial clearance of Zyn pouches in 2025, when officials determined that benefits to adult cigarette smokers outweighed risks to adults and youth, based partly on the finding that the pouches contain fewer harmful chemicals than cigarettes.

Scientific Review and Authorization Process

The FDA's authorization followed an extensive scientific review process. According to the announcement, regulators concluded that Swedish Match demonstrated the modified risk claim was scientifically accurate, that consumers understand the claim, and that marketing the products with the claim would benefit the population.

An FDA advisory panel reviewed the proposed statement in January 2026 and said the claim was likely accurate. The Campaign for Tobacco Free Kids opposed the proposal at the time, arguing that Swedish Match did not meet the standard for authorization. The nonprofit contended there was no demonstrated benefit, among other concerns.

Despite this opposition, the FDA proceeded with the authorization based on its scientific review findings.

Requirements and Monitoring

The authorization includes specific requirements for Swedish Match. The company must carry out studies and surveillance, including assessing how people interact with the updated products and understand the updated risk-related information.

The authorization lasts for five years and can be extended. If the FDA determines that marketing under the adjusted statement no longer benefits the population, such as a scenario involving a spike in uptake among young people, the agency may withdraw the authorization, officials said.

These monitoring requirements reflect the FDA's ongoing concern about youth access and uptake of nicotine products. The agency's ability to withdraw authorization based on changes in usage patterns provides a regulatory mechanism to respond to unintended consequences.

Industry and Advocacy Response

Philip Morris CEO Stacey Kennedy hailed the development, stating it ensures adults have access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to Zyn reduces the risk of smoking-related diseases like heart disease and lung cancer.

Kennedy said the decision reinforces the agency's science-based approach to evaluating products across the continuum of risk and communicating those findings transparently.

The tobacco control advocacy community had expressed concerns during the review process. The Campaign for Tobacco Free Kids' opposition highlighted ongoing debates about modified risk tobacco products and the standards for authorization.

What to Watch Next

For readers following broader market updates , this development can help frame the wider regulatory context.

The required studies and surveillance data that Swedish Match must conduct and report to the FDA will be important to monitor. These studies will assess consumer understanding of the modified risk claim and track usage patterns, particularly among youth. Any significant increase in youth uptake could trigger FDA reconsideration of the authorization.

Future FDA decisions on modified risk applications from other nicotine product manufacturers will indicate whether this authorization represents a broader shift in regulatory approach or a product-specific determination. The renewal decision when the five-year authorization period expires will also be significant.

Read original source